Key points that were discussed include:
- Current and emerging M&A trends
- Valuation considerations
- Deal terms and risks
Speakers:
- James Bertram, Head of Consumer and Retail, Corporate Finance, William Blair & Company
- Catherine Eley, Partner, Eversheds LLP
- Theresa-Marie Stodell, Associate, Eversheds LLP
- James Peterson, Partner, Foley & Lardner LLP
Foley & Lardner LLP will apply for CLE credit after the program, wherever applicable. Foley & Lardner LLP certifies that this activity has been approved for California MCLE credits by the State Bar of California in the amount of one General credit. Foley & Lardner LLP is a State Bar of California MCLE approved provider. Please note that participants must log in to both the teleconference and LiveMeeting portions on the date of the event; credit may not be obtained by viewing and/or listening to a program recording after the event.
People
Related Insights
June 3, 2025
Foley Corporate Governance Update
Texas Senate Bill 2337: Protecting Texas Companies and Their Directors, Shareholders and Boards from Proxy Advice Not in the Financial Interests of Shareholders
On June 2, 2025, the Texas Legislature passed Senate Bill 2337, meaningfully regulating proxy advisors like ISS and Glass Lewis when providing proxy voting recommendations concerning Texas companies.
September 25, 2025
Events
Unclaimed Property Roundtable with Delaware State Escheator and Leading Practitioners
June 3, 2025
Health Care Law Today
GLP-1 Receptor Agonists: The Surge of M&A Activity and the Future of Metabolic Health
Over the past decade, the global pharmaceutical industry has witnessed a transformation in the treatment landscape for metabolic disorders, particularly type 2 diabetes and obesity.